A Study to Examine the Efficacy and Safety of REGN5069 in Patients With Pain Due to Osteoarthritis of the Knee
A Randomized, Double-Blind, Multi-Dose, Placebo-Controlled Study to Evaluate the Efficacy and Safety of REGN5069 in Patients With Pain Due to Osteoarthritis of the Knee
Sponsor: Regeneron Pharmaceuticals
Terminated
Regeneron has discontinued further clinical development of REGN5069, an antibody to GFRα3, which was previously being studied in osteoarthritis pain of the knee
Other terminated trials from Regeneron Pharmaceuticals
Other Osteoarthritis of the Knee trials with similar outcome
This PHASE2 trial investigates Osteoarthritis of the Knee and Pain and is currently terminated or withdrawn. Regeneron Pharmaceuticals leads this study, which shows 14 recorded versions since 2019 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
14 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Dec 2021 — Jul 2024 [monthly]
Terminated PHASE2
-
Sep 2021 — Dec 2021 [monthly]
Terminated PHASE2
▶ Show 9 earlier versions
-
Jan 2021 — Sep 2021 [monthly]
Terminated PHASE2
-
Dec 2020 — Jan 2021 [monthly]
Terminated PHASE2
Status: Active Not Recruiting → Terminated
-
Oct 2020 — Dec 2020 [monthly]
Active Not Recruiting PHASE2
-
Jun 2020 — Oct 2020 [monthly]
Active Not Recruiting PHASE2
-
May 2020 — Jun 2020 [monthly]
Active Not Recruiting PHASE2
-
Apr 2020 — May 2020 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Jan 2020 — Apr 2020 [monthly]
Recruiting PHASE2
-
Jul 2019 — Jan 2020 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Jun 2019 — Jul 2019 [monthly]
Not Yet Recruiting PHASE2
First recorded
May 2019
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Regeneron Pharmaceuticals
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Bialystok, Poland , Charleston, United States , Chisinau, Moldova , DeLand, United States , Jupiter, United States , Kyiv, Ukraine , Lublin, Poland , Miami, United States , Tbilisi, Georgia , Warsaw, Poland and 2 more locations